

# Fbx15 Is a Novel Target of Oct3/4 but Is Dispensable for Embryonic Stem Cell Self-Renewal and Mouse Development

Yoshimi Tokuzawa,<sup>1</sup> Eiko Kaiho,<sup>1</sup> Masayoshi Maruyama,<sup>1</sup> Kazutoshi Takahashi,<sup>1</sup> Kaoru Mitsui,<sup>1</sup> Mitsuyo Maeda,<sup>2</sup> Hitoshi Niwa,<sup>3</sup> and Shinya Yamanaka<sup>1\*</sup>

Laboratory of Animal Molecular Technology, Research and Education Center for Genetic Information, Nara Institute of Science and Technology, Ikoma, Nara 630-0192,<sup>1</sup> First Department of Anatomy, Osaka City University Medical School, Osaka 545-8585,<sup>2</sup> and Laboratory of Pluripotent Cell Studies, RIKEN Center for Developmental Biology, Kobe, Hyogo 650-0047,<sup>3</sup> Japan

Received 8 August 2002/Returned for modification 1 November 2002/Accepted 19 December 2002

**Embryonic stem (ES) cells are immortal and pluripotent cells derived from early mammalian embryos. Transcription factor Oct3/4 is essential for self-renewal of ES cells and early mouse development. However, only a few Oct3/4 target genes have been identified. In this study, we found that F-box-containing protein Fbx15 was expressed predominantly in mouse undifferentiated ES cells. Inactivation of *Oct3/4* in ES cells led to rapid extinction of *Fbx15* expression. Reporter gene analyses demonstrated that this ES cell-specific expression required an 18-bp enhancer element located approximately 500 nucleotides upstream from the transcription initiation site. The enhancer contained an octamer-like motif and an adjacent Sox-binding motif. Deletion or point mutation of either motif abolished the enhancer activity. The 18-bp fragment became active in NIH 3T3 cells when Oct3/4 and Sox2 were coexpressed. A gel mobility shift assay demonstrated cooperative binding of Oct3/4 and Sox2 to the enhancer sequence. In mice having a  $\beta$ -galactosidase gene knocked into the *Fbx15* locus, 5-bromo-4-chloro-3-indolyl- $\beta$ -D-galactopyranoside staining was detected in ES cells, early embryos (two-cell to blastocyst stages), and testis tissue. Despite such specific expression of *Fbx15*, homozygous mutant mice showed no gross developmental defects and were fertile. *Fbx15*-null ES cells were normal in morphology, proliferation, and differentiation. These data demonstrate that *Fbx15* is a novel target of Oct3/4 but is dispensable for ES cell self-renewal, development, and fertility.**

Embryonic stem (ES) cells are derived from mammalian blastocysts and maintain pluripotency, an ability to differentiate into all types of somatic and germ cells (32). Another important property of ES cells is their robust and infinite growth equivalent to tumor cells despite their normal karyotype. ES cells were developed from mouse blastocysts in 1981 (8, 15) and have been extensively used to generate knockout mice. Human ES cells were established in 1998 (33) and are considered promising sources for cell transplantation therapy.

POU transcription factor Oct3/4 is expressed specifically in pluripotent cells, including ES cells, early embryos, and germ cells (27, 31). Targeted disruption of the *Oct3/4* gene in the mouse results in early embryonic lethality (21). The inner cellular mass of *Oct3/4*-null blastocysts differentiates exclusively into trophoblasts. Furthermore, conditional deletion of *Oct3/4* in ES cells leads to spontaneous differentiation into trophectoderm (25), demonstrating that Oct3/4 is essential for self-renewal of ES cells and mouse early development.

Only a few Oct3/4 target genes have been identified. These include *FGF-4* (4) and *Rex-1* (2), in which Oct3/4 binds to an octamer motif, ATT(T/A)GCAT, located in regulatory elements. In *FGF-4*, SRY-related transcription factor Sox2 binds to a motif adjacent to the octamer sequence and synergistically activates transcription (5). In *Rex-1*, hypothetical factor ROX1

functions in a similar manner (2). It is not clear whether synergistic interaction with other transcription factors is common among target genes. Even consensus nucleotide sequences of Oct3/4-binding sites have not been fully determined. For example, the Oct3/4-binding site in *UTF1* is one nucleotide different from the octamer sequence (22). Furthermore, it remains largely unknown how Oct3/4 maintains self-renewal of ES cells. Identification of novel Oct3/4 target genes is crucial to answering these questions.

In this study, we utilized expression analyses, reporter gene analyses, and a gel mobility shift assay to demonstrate that *Fbx15*, which encodes an F-box-containing protein (35), is a novel target of Oct3/4. We also performed gene-targeting experiments to study physiological functions of Fbx15 in self-renewal of ES cells, mouse development, and fertility.

## MATERIALS AND METHODS

**Digital Differential Display.** We utilized the Digital Differential Display program ([http://www.ncbi.nlm.nih.gov/UniGene/info\\_ddd.shtml](http://www.ncbi.nlm.nih.gov/UniGene/info_ddd.shtml)) to analyze gene representation in cDNA libraries from ES cells and other tissues. Expressed sequence tag (EST) libraries derived from ES cells were no. 274 and 220 (a total of 27,705 entries). Libraries used to represent various somatic tissues were no. 467, 318, 198, 408, 239, 400, 453, 109, 16, 523, 161, 483, 258, 264, 419, 529, 327, 411, 417, 418, 399, 196, 271, 255, 495, 101, 98, 351, 416, 321, 251, 412, 379, 549, 329, 265, 449, 328, 516, 320, 436, 427, 297, 366, 390, 315, 228, 277, 292, 284, 285, and 30 (a total of 1,328,835 entries).

**Cell culture.** The RF8 (16), JI (13), CGR8 (20), and MG1.19 (9) ES cell lines were cultured as previously described. Differentiation of ES cells was induced with retinoic acid as previously described (36). NIH 3T3 cells were cultured with Dulbecco's modified Eagle medium (Sigma) containing 10% fetal bovine serum (Sanko Junyaku, Tokyo, Japan) and maintained at 37°C with 5% CO<sub>2</sub>.

\* Corresponding author. Mailing address: Laboratory of Animal Molecular Technology, Research and Education Center for Genetic Information, Nara Institute of Science and Technology, Ikoma, Nara 630-0101, Japan. Phone: 81-743-72-5591. Fax: 81-743-72-5599. E-mail: shinyay@gtc.aist-nara.ac.jp.

**Northern blot analyses.** Total RNAs were prepared from RF8 and MG1.19 ES cells with Trizol (Invitrogen). Total RNAs from untreated and tetracycline-treated ZHBTc4 ES cells were prepared as previously described (23). Total RNAs from 12 adult mouse tissues were purchased from Sawady Technology (Tokyo, Japan) and Funakoshi (Tokyo, Japan). Northern blot analyses were performed with formalin agarose gels as previously described (36, 37). As a probe, we used a *NotI/SalI* fragment of an EST clone (accession number AA571680) containing *Fbx15* cDNA.

**Reverse transcription (RT)-PCR.** First-strand cDNA was synthesized from total RNA with ReverTra Ace- $\alpha$  (Toyobo). *Fbx15*, *Oct3/4*, and *NAT1* were amplified with primers U1110 and L1431, *Oct3-U474* and *Oct3-L935*, and *NAT1-U10* and *NAT1-L21*, respectively. The sequences of the primers used in this study are available upon request.

**Western blot analyses.** ES cell extracts were prepared with M-Per (Pierce), separated on sodium dodecyl sulfate (SDS)-14% polyacrylamide gels, and transferred to nitrocellulose membranes (Millipore). The primary antibodies used were anti-Skp1 (SC1568, 1/600 dilution; Santa Cruz), anti-hemagglutinin (anti-HA; SC1568, 1/600; Roche), anti-myc (SC789, 1/600; Santa Cruz), and anti-GST (SC459, 1/2,000; Santa Cruz). The secondary antibodies used were horseradish peroxidase-conjugated anti-rabbit immunoglobulin G (SC2030, 1/5,000; Santa Cruz) and horseradish peroxidase-conjugated anti-rat immunoglobulin G (SC2006, 1/5,000; Santa Cruz).

**5' RACE.** *Fbx15* transcription initiation sites in ES cells were determined with the 5' rapid amplification of cDNA ends (5' RACE) system, version 2.0 (Invitrogen). The primers used were L1102 for cDNA synthesis and L782 and L350 for PCR.

**Determination of the nucleotide sequence of the 5' flanking region.** A bacterial artificial chromosome (BAC) clone containing the *Fbx15* gene was identified from mouse BAC library DNA pools (Research Genetics) by PCR-based screening with primers U889 and L1102. BAC DNA was directly sequenced with primers *Fbx-AS1*, *Fbx-AS2*, *Fbx-AS3*, and *Fbx-AS4* as previously described (37).

**Construction of luciferase reporter plasmids.** A DNA fragment (−526 to +145) was amplified from the BAC clone by PCR with primers *mFbx-pro.U637* and *mFbx-pro.L1337* and cloned into *pCR2.1* (Invitrogen). An *EcoRI/MunI* fragment of this was cloned into the *EcoRI* site of *pGV-BM2*, which we made from *pGV-B* (Promega) by inserting an *EcoRI/XbaI* linker into the *KpnI* site. The resulting plasmid was designated *p(−526/+114)LUC* and used to construct reporter plasmids with longer fragments as follows. PCR products amplified from the BAC clone with the primers described below were cloned into the *pCR2.1* vector. DNA inserts were then isolated by *EcoRI* digestion and cloned into the *EcoRI* site of *p(−526/+114)LUC*. The upper primers used were *Fbx-pro.U95* and *Fbx-pro.U 573* for DNA fragments starting at positions −1120 and −640. The common lower primer used was *mFbx-pro.L688*, whose 5' end was at position −504.

**Construction of reporter plasmids with *Fbx15* enhancer and minimum thymidine kinase promoter.** A PCR product amplified from the BAC clone with primers *Fbx-pro.U573* and *mFbx-pro.L688* was cloned into *pCR2.1*. An *EcoRI* fragment of the resulting plasmid, which contained the *Fbx15* enhancer (−640 to −527), was blunt end ligated into the *BglII* site of *pTA-Luc* (Clontech). We constructed reporter plasmids with deleted or mutated sequences by inserting various linkers into the *MluI/BglII* site of *pTA-Luc*. The linker sequences are available upon request.

**Construction of entry vectors for the Gateway cloning system.** We utilized Gateway cloning technology (Invitrogen) to construct expression vectors for various genes. In this method, genes of interest were first cloned into *pDONR201* to construct entry vectors, which were then recombined with destination vectors to construct expression vectors. Coding regions of *Fbx15*, *Skp1*, and *Cul1* were amplified by PCR from EST clones (accession numbers: AA571680 for *Fbx15*, AA08144 for *Skp1*, and BE533604 for *Cul1*). The primers used were *fbx-gw-S* and *fbx-gw-AS* for *Fbx15*, *fbx-c-gw-S* and *fbx-c-gw-AS* for the C-terminal portion of *Fbx15* (amino acids 297 to 473), *Skp1-gw-S* and *Skp1-gw-AS* for *Skp1*, and *Cul1-gw-S* and *Cul1-gw-AS* for *Cul1*. *Sox2* cDNA was amplified by RT-PCR from mouse ES cell total RNA with primers *Sox-2-gw-S* and *Sox-2-gw-AS*. The PCR products were reamplified with primers *attB1-AD* and *attB2-AD* and cloned into *pDONR201* to construct *pDONR-Fbx15*, *pDONR-Fbx15C*, *pDONR-Skp1*, *pDONR-Cul1*, and *pDONR-Sox2*.

**Construction of destination vectors for the Gateway cloning system.** An *NdeI/EcoRI* fragment of *pCX-EGFP* (enhanced green fluorescent protein) containing the CAG promoter (26) was inserted into the same site of *pIRES-neo* (Clontech) to construct *pCAG-IRES-neo*. The Gateway *refA* cassette was blunt end ligated into the *EcoRI* site to construct *pCAG-gw-IRES-neo*. The Gateway *refC* cassette was blunt end ligated into the *EcoRI/XbaI* site of *pCS2+MT* (17) to construct *pMyc-gw*. An *NheI/BamHI* fragment of *pEGFP-C2* (Clontech) was inserted into

the same site of *pCDNA3.1* (Clontech) to construct *pCDNA3.1-EGFP*. The Gateway *refC* cassette was blunt end ligated into the *XhoI* site of *pCDNA3.1-EGFP* to construct *pCDNA3.1-EGFP-gw*. *pDEST17* was purchased from Invitrogen.

**Construction of expression vectors.** The expression vectors constructed by a recombination reaction between the entry vectors and destination vectors were *pMyc-Fbx15*, *pMyc-Skp1*, *pCAG-EGFP-Skp1*, *pDEST17-Fbx15C*, and *pCAG-Sox2-IRES-neo*. *pCAG-Oct3/4-IRES-neo* was constructed as follows. An *EcoRI/BclII* fragment of the plasmid containing *Oct3/4* cDNA (27) was inserted into the *EcoRI/BamHI* site of *pIRES-neo* (Clontech) to construct *pCMV-Oct3/4-IRES-Neo*. An *NdeI/EcoRI* fragment of *pCAG-IRES-Neo* containing the CAG promoter was inserted into the same site of *pCMV-Oct3/4-IRES-Neo* to construct *pCAG-Oct3/4-IRES-Neo*.

**Construction of episomal expression plasmids.** *BamHI/NotI* fragments of *pMyc-Fbx15* and *pMyc-Skp1* and an *Eco47III/XbaI* fragment of *pCAG-EGFP-Skp1* were blunt end ligated into the *XhoI* site of *pCAGIP* (24) to construct *pCAGIP-Myc-Fbx15*, *pCAGIP-Myc-Skp1*, and *pCAGIP-EGFP-Skp1*. *pCAGIP-HA-gw* (K. Takahashi et al., unpublished data) was recombined with *pDONR-Cul1* and *pDONR-Fbx15* by LR reaction to construct *pCAGIP-HA-Cul1* and *pCAGIP-HA-Fbx15*.

**Luciferase reporter assay.** DNA transfection into ES and NIH 3T3 cells was performed with Lipofectamine 2000 (Invitrogen) in accordance with the manufacturer's protocol. After 24 h, cell lysates were collected and luciferase activity was measured with the Dual-Luciferase Reporter Assay System (Promega) as described elsewhere (37).

**Immunoprecipitation.** Twenty-microgram samples of expression vectors were introduced into MG1.19 ES cells grown in 10-cm-diameter dishes. After 24 h, cell lysates were corrected with 500  $\mu$ l of M-PER (Pierce) supplemented with 10  $\mu$ l of protease inhibitor cocktail (Nacalai Tesque). Myc-tagged proteins were precipitated with agarose-conjugated anti-myc antibody sc40AC (Santa Cruz), separated by SDS-polyacrylamide gel electrophoresis (PAGE), and analyzed by Western blotting.

**Generation of anti-Fbx15 polyclonal antibody.** *pDEST17-Fbx15C* was transformed into BL21-SI (Invitrogen). Recombinant protein was induced in accordance with the manufacturer's protocol. Purification of histidine-tagged *Fbx15C* was performed with Ni-nitrilotriacetic acid agarose (Qiagen) under denaturing conditions. In brief, cells were lysed with buffer A and incubated with Ni-nitrilotriacetic acid resin. After washing with buffers C and D, histidine-tagged protein was eluted with buffer E. Purified proteins were dialyzed in phosphate-buffered saline containing 6 M urea overnight at 4°C. New Zealand White rabbits were immunized with this recombinant protein to generate anti-Fbx15 serum.

**Gel mobility shift assay.** *pCAGIP-HA-Oct3/4* and *pCAGIP-HA-Sox2* (M. Maruyama et al., unpublished data) were introduced into Cos7 cells with Fugene 6 (Roche). Cell lysates were collected with extraction buffer (20 mM HEPES [pH 7.8], 450 mM NaCl, 0.4 mM EDTA, 0.5 mM dithiothreitol, 25% glycerol, 0.5 mM phenylmethylsulfonyl fluoride) supplemented with protease inhibitor cocktail and then dialyzed to remove salt. F9 embryonic carcinoma cell extract was purchased from Funakoshi. The DNA mobility shift assay was performed as described by Dent and Latchman (7), except that 0.5 $\times$  Tris-borate-EDTA buffer was used for electrophoresis, gels were prerun for 10 min, and poly(dG-dC) was used instead of poly(dI-dC).

**Targeted disruption of the mouse *Fbx15* gene.** A targeting vector with promoter trap selection was designed to replace exons 3 to 7 of the mouse *Fbx15* gene, which contain the F-box domain, with an IRES (internal ribosome entry site)- $\beta$ -*geo* (fusion of  $\beta$ -galactosidase [ $\beta$ -gal]- and neomycin resistance-encoding genes) cassette (19). A 1.4-kbp fragment containing intron 1 to exon 3 and a 3.5-kbp fragment containing exons 7 and 8 were amplified from the BAC clone and used as the 5' and 3' homologous regions of the targeting vector. The 5' arm was amplified by using a TOPO Walker Kit (Invitrogen) with primer L289 for extension and nested primer L255 for PCR. The 3' arm was amplified by PCR with primers U939 and L1102. An IRES- $\beta$ -*geo* cassette was ligated between the two DNA fragments. The resulting targeting vector was linearized by *NotI* digestion and introduced into RF8 ES cells by electroporation (16). Genomic DNAs from G418-resistant colonies were screened for homologous recombination by Southern blot analyses. For 5' recombination, genomic DNA was digested with *HindIII*, separated on a 0.8% agarose gel, and transferred to a nylon membrane. Hybridization with a 600-bp probe from intron 1 produced a 10-kbp band from the wild-type locus and an 8-kbp band from the targeted locus. For 3' recombination, the same membrane was hybridized with a 300-bp probe from intron 8, which produced a 9-kbp band from the wild-type locus and a 10-kbp band from the targeted locus.

**Genotyping of mice and ES cells.** After identifying ES cell clones that were correctly targeted, we determined genotypes of mice and ES cells with a three-




FIG. 1. (A) RT-PCR analysis showing the expression profiles of mouse *Oct3/4*, *Fbx15*, and *NAT1*. Lanes: a, undifferentiated ES cells; b, differentiated ES cells; c, brain; d, heart; e, kidney; f, testis; g, spleen; h, muscle; i, lung; j, stomach; k, ovary; l, thymus; m, liver; n, skin. (B) Western blot analysis showing *Fbx15* expression in the RF8, J1, CGR8, and MG1.19 ES cell lines. Lysates were collected from ES cells maintained undifferentiated (lanes 0) or treated with retinoic acid for 5 days (lanes 5). Western blotting was performed with anti-Fbx15 serum or anti-CDK4 antibody.

primer PCR. The first sense primer,  $-/-$ -screeningS2, was designed from intron 6 to amplify the wild-type locus. The second sense primer,  $\beta$ -geo screening1, was designed from the  $\beta$ -geo cassette to amplify the targeted locus. A single antisense primer,  $-/-$ -screeningAS2, was designed from intron 7 to amplify both the wild-type and targeted loci. PCR with these primers produces a 280-bp fragment from the wild-type locus and a 725-bp fragment from the targeted locus. PCR was performed with the Expand Long Template PCR system (Roche) in accordance with the manufacturer's protocol. The PCR program consisted of initial denaturation at 94°C for 2 min; 35 cycles of 94°C for 30 s, 53°C for 30 s, and 68°C for 1 min; and a final extension at 68°C for 7 min.

## RESULTS

To isolate candidate genes that are expressed specifically in mouse ES cells under control of *Oct3/4*, we used digital differential display to compare gene representation between EST libraries derived from ES cells and those from various somatic tissues. We identified several genes that appeared only in ES cell-derived libraries. One of the candidate genes encoded Fbx15, a protein with an F-box domain (35). A BLAST search against whole-mouse dbEST databases (22 July 2000) with the full-length *Fbx15* cDNA sequence as a query identified 16 cDNA clones corresponding to *Fbx15* in libraries from ES cells and 39 clones in libraries from preimplantation embryos (16 2-cell embryo, 15 8-cell embryo, 2 16-cell embryo, and 6 blastocyst libraries [numbers of clones with scores of >200 bits]) but none in unfertilized egg, in vitro-fertilized egg, and other libraries.

To determine whether *Fbx15* is indeed expressed predominantly in ES cells, we studied its expression level by RT-PCR analyses. We found a high level of *Fbx15* expression in MG1.19 ES cells (16) (Fig. 1A). Upon differentiation induced with retinoic acid, *Fbx15* expression was repressed. Testis tissue also expressed *Fbx15* but at a level lower than that at which undif-




FIG. 2. Expression of *Fbx15* in ZHBTc4 ES cells. Cells were treated with tetracycline, and the expression of *Oct3/4* and *Fbx15* was determined at the indicated time points by Northern blot analysis. Ethidium bromide staining of rRNAs was used as a loading control.

ferentiated ES cells did. There was faint expression in ovary tissue. No expression was detected in 10 other tissue types from adult mice. This *Fbx15* expression pattern was nearly identical to that of *Oct3/4* (Fig. 1A).

To confirm specific expression in ES cells at the protein level, we generated rabbit polyclonal antibody against the C-terminal portion (amino acids 297 to 473) of mouse Fbx15. Western blot analyses with the antiserum detected a single band of 55 kDa in four independent ES cell lines, RF8, J1, CGR8, and MG1.19 (Fig. 1B). Upon differentiation induced by retinoic acid, the Fbx15 protein disappeared in all four lines (Fig. 1B), confirming undifferentiated cell-specific expression at the protein level.

To study a putative role of *Oct3/4* in the ES cell-specific expression of *Fbx15*, we utilized ZHBTc4 ES cells, in which both copies of the *Oct3/4* gene were deleted while self-renewal was maintained by tetracycline-controlled expression of *Oct3/4* (25). Because of a cryptic polyadenylation site, the transgene produced two transcripts that both encoded functional *Oct3/4* protein (Fig. 2). Upon addition of tetracycline to the culture medium, the longer and shorter transcripts disappeared within 24 and 72 h, respectively. Expression of *Fbx15* also disappeared within 72 h after tetracycline addition. This result suggests that *Oct3/4* controls the expression of *Fbx15* in ES cells.

To further study the role of *Oct3/4* in ES cell-specific expression of *Fbx15*, we analyzed the 5' flanking region of the *Fbx15* gene. We first determined the transcription initiation site by 5' RACE. We obtained a single band from a PCR using gene-specific primers (data not shown), which was cloned into plasmid pCR2.1. We sequenced 10 clones and found that 7 of them started 17 nucleotides upstream from the 5' end of the reported sequence. We consider this position a major transcription initiation site and refer to it as position +1 hereafter. Three other clones started at positions -26, -30, and -199, suggesting that multiple minor initiation sites also exist. TFSEARCH (<http://www.cbrc.jp/research/db/TFSEARCHJ.html>) identified a putative binding site of the Sox family of transcription factors, AACAAT, between positions -534 and -528. It is noteworthy that an octamer-like sequence, TTTATCAT, was located immediately upstream of the Sox-binding site.




FIG. 3. Reporter gene analyses to define the *Fbx15* enhancer. DNA fragments starting at positions  $-1120$ ,  $-640$ , and  $-526$  and ending at position  $+114$  of the *Fbx15* gene were placed in front of the firefly luciferase gene. These reporter constructs were introduced into undifferentiated ES cells. Shown is fold induction of normalized luciferase activity compared to that of the promoterless construct (pGV-BM2). Diagonally striped boxes represent the octamer-like and Sox-binding motifs.

To study the roles of the octamer-like sequence and the Sox-binding motif, we constructed luciferase reporter vectors with DNA fragments that started at positions  $-1120$ ,  $-640$ , and  $-526$ . These constructs were introduced into undifferentiated ES cells. The DNA fragment starting at position  $-640$  showed marked enhancement in a luciferase activity compared to that starting at  $-526$  (Fig. 3). Only a small enhancement was observed with the fragment starting at  $-1120$ . All constructs were inactive in differentiated ES cells and NIH 3T3 cells (data not shown). These data indicate that the DNA fragment ( $-640$  to  $-527$ ) containing the octamer-like motif and the Sox-binding site is essential for ES cell-specific expression of *Fbx15*.

To further define the enhancer element, we located a DNA fragment corresponding to positions  $-640$  to  $-527$  and various deleted and/or mutated fragments into reporter constructs that contained luciferase cDNA driven by the minimum thymidine kinase promoter. The longest (114-bp) fragment was able to enhance luciferase activity in RF8 ES cells but not in differentiated ES cells or NIH 3T3 cells (Fig. 4). The same fragment inserted in the opposite orientation failed to enhance luciferase activity. Analyses by serial deletion demonstrated that the enhancer is located in an 18-bp fragment between positions  $-544$  and  $-527$  that contains the Sox-binding site and the octamer-like motif. Deletion of either of these two sites abolished the enhancer activity (Fig. 4). Furthermore, point mutation of the octamer-like sequence to TCCCTCAT or the Sox-binding site to AACCAT or ACCCAT (mutations are underlined) also abolished enhancer activity (Fig. 5). These data indicate that the octamer-like motif and the Sox-binding site are essential for the enhancer activity of *Fbx15*.

We next investigated whether Oct3/4 and Sox2 can activate the *Fbx15* enhancer. We constructed a reporter gene in which the luciferase gene was driven by the minimum thymidine kinase promoter and five copies of the *Fbx15* enhancer. When this construct was introduced into NIH 3T3 cells, luciferase activity was the same as the background level (Fig. 6). When it




FIG. 4. Enhancer analyses with the minimal thymidine kinase (TK) promoter. DNA fragments of various sizes were isolated from the *Fbx15* gene and placed in front of the firefly luciferase gene driven by the minimal thymidine kinase promoter. These reporter constructs were introduced into undifferentiated ES cells (black column), differentiated ES cells (gray), and NIH 3T3 cells (white). Shown is fold induction of normalized luciferase activity compared to that of the enhancerless construct (pTA-Luc). Diagonally striped boxes represent the octamer-like and Sox-binding motifs.

was transfected together with an Oct3/4 or Sox2 expression vector, no enhancement was observed. However, when it was cotransfected with both the Oct3/4 and Sox2 expression vectors, significant enhancement of luciferase activity was achieved. In contrast, Oct3/4 and Sox2 did not enhance a reporter gene that contained a single-nucleotide modification in the Sox-binding site. These data, taken together, demonstrate that Oct3/4 and Sox2 synergistically activated the *Fbx15* enhancer.

To further confirm the direct activation of the *Fbx15* enhancer by Oct3/4 and Sox2, we performed a gel mobility shift assay. To determine the positions of bands corresponding to Oct3/4, Sox2, and their complex, we incubated  $^{32}\text{P}$ -labeled *FGF-4* enhancer oligonucleotides with Cos7 cell extracts expressing Oct3/4, Sox2, or both (Fig. 7, left). When we incubated  $^{32}\text{P}$ -labeled *Fbx15* enhancer oligonucleotides with a Cos7 extract expressing Oct3/4 alone, no shifted band was observed (Fig. 7 center). In contrast, when they were incubated with cell extracts expressing both Oct3/4 and Sox2, a shifted band corresponding to the complex was observed. This band was abolished by mutation either in the octamer-like sequence or in




FIG. 5. Effects of point mutations in the octamer-like sequence or the Sox recognition motif. Reporter plasmids containing the *Fbx15* enhancer sequence (WT) or mutated sequences (Oct-m, Sox-m1, and Sox-m2) were analyzed as described in the legend to Fig. 4.

the Sox-binding site. When we incubated the <sup>32</sup>P-labeled *Fbx15* enhancer oligonucleotides with nuclear extracts of F9 embryonic carcinoma cells, we observed two shifted bands at the positions corresponding to the Oct3/4-Sox2 complex and the Sox2 monomer (Fig. 7, right). Both bands were eliminated by an excess amount of unlabeled *Fbx15* enhancer oligonucleotides. Mutation either in the octamer-like sequence or in the Sox-binding site abolished the band corresponding to the Oct3/4-Sox2 complex. As expected, the band corresponding to the Sox2 monomer was abolished by the Sox mutation but not by the octamer mutation. These results demonstrate that Oct 3/4 directly binds to the *Fbx15* enhancer with the help of Sox2.

We next analyzed the functions of Fbx15. We first determined whether Fbx15 is a component of the SCF complex, as was the case with other F-box-containing proteins (1, 14). We constructed expression vectors of myc-tagged Fbx15, HA-tagged Cul1, and EGFP-tagged Skp1 and introduced them into MG1.19 ES cells. Expression of transgenes in cell lysates was confirmed by Western blotting with anti-Skp1, anti-HA, and anti-myc antibodies, respectively (Fig. 8). When myc-Fbx15 was immunoprecipitated with anti-myc antibody, both HA-cul1 and EGFP-Skp1 were copurified. In contrast, when myc-Fbx15 was omitted from the transfection, neither HA-Cul1 nor EGFP-Skp1 was precipitated with the anti-myc antibody. The association between Fbx15 and Skp1 was also demonstrated in the opposite direction. When myc-Skp1 and HA-Fbx15 were




FIG. 6. Activation of the *Fbx15* enhancer by Oct3/4 and Sox2 in NIH 3T3 cells. Reporter plasmids containing five copies of the *Fbx15* enhancer sequence (WT) or a mutated sequence (Sox-m1) were introduced into NIH 3T3 cells with or without Oct3/4 and/or Sox2 expression vectors. Luciferase activities were analyzed as described in the legend to Fig. 4.

expressed and myc-Skp1 was precipitated, HA-Fbx15 was copurified (data not shown). These data indicate that Fbx15 forms the SCF complex.

To elucidate the in vivo functions of Fbx15, we disrupted its mouse gene by homologous recombination. To this end, we constructed a targeting vector that replaced exons 3 to 7 containing the F box with a  $\beta$ -geo cassette (Fig. 9A). By introducing this vector into RF8 ES cells, we obtained 2 correctly targeted clones out of 200 screened. Both 5' and 3' junctions were confirmed by Southern blot analyses (Fig. 9B). These cells were injected into C57BL/6 blastocysts, and germ line transmission was obtained from one clone. Homozygous mutant mice were born from heterozygous intercrossing in accordance with Mendel's ratio (+/+, 22; +/-, 43; -/-, 18 [out of 83 examined]) and showed no gross abnormalities. Both male and female homozygous mice were fertile. These data showed that Fbx15 is not required for mouse development or fertility.

To study the functions of Fbx15 in ES cells, we established homozygous mutant ES cells by selecting heterozygous cells with a high concentration (6 mg/ml) of G418 (18). We obtained two homozygous clones (Fig. 9C). Northern (Fig. 9D) and




FIG. 7. Gel mobility shift assay. A  $^{32}\text{P}$ -labeled oligonucleotide (WT; ccagatgtgcTTTATCATAACAATGgaattctaggggct) corresponding to the *Fbx15* enhancer was incubated with F9 EC cell extract or Cos7 cell extract expressing Oct3/4, Sox2, or both. Oligonucleotides with mutations (underlined) in the octamer-like sequence [O (-); ccagatgtgcTCCCTCATAACAATGgaattctaggggct] and the Sox-binding site [S (-); ccagatgtgcTTTATCATAACCATGgaattctaggggct] were also tested. As a control, an *FGF-4* enhancer oligonucleotide (ttaagatcccATTAGCATccaAACAAAGagtttcta) was incubated with Cos7 cell extracts expressing Oct3/4, Sox2, or both. Shown on the left are the positions of bands corresponding to each transcription factor(s). The nature of the faint band indicated by the asterisk is not known. cold WT, unlabeled oligonucleotide corresponding to the *Fbx15* enhancer.

Western (Fig. 9E) blot analyses demonstrated that *Fbx15* transcripts and proteins were absent in both clones. Homozygous mutant cells were normal in morphology (Fig. 10A), *Oct3/4* expression (Fig. 9D), and proliferation (data not shown). They were differentiated normally by retinoic acid (Fig. 10A) and formed normal embryoid bodies (data not shown). Furthermore, when injected subcutaneously into nude mice, they formed teratomas (5, 6) consisting of all three germ layers (data not shown).

We used mutant ES cells and mice to examine the expression profile of *Fbx15* by means of the  $\beta$ -gal cassette knocked into the *Fbx15* locus. Undifferentiated mutant ES cells showed strong  $\beta$ -gal activity (Fig. 10A). Upon differentiation, the activity was lost, indicating that  $\beta$ -gal expression mimicked the endogenous expression of *Fbx15*. In adult mice, 5-bromo-4-chloro-3-indolylphosphate (X-Gal) staining was only detected in testis tissue (Fig. 10B). No  $\beta$ -gal activity was detected in unfertilized eggs or fertilized one-cell stage eggs (Fig. 10C). X-Gal staining started to appear in two-cell stage embryos and reached a maximum in eight-cell embryos and blastocysts. These results confirmed that *Fbx15* is specifically expressed in ES cells, early embryos, and testis tissue.

We also examined the function of *Fbx15* in ES cells by a gain-of-function approach. We generated ES cells constitutively expressing *Fbx15* cDNA from the CAG promoter. These




FIG. 8. Western blot analyses showing association of *Fbx15* with Skp1 and Cul1. MG1.19 cells were transfected with myc-*Fbx15*, HA-Cul1, and EGFP-Skp1 expression vectors. Cell lysates and anti-myc antibody immunoprecipitates (IP) were separated by SDS-PAGE and immunoblotted with anti-Skp1 (top), anti-HA (middle), and anti-myc (bottom) antibodies. In a negative-control experiment, myc-*Fbx15* was omitted from the transfection reaction mixture.




FIG. 9. Targeted disruption of the mouse *Fbx15* gene. (A) Structures of the *Fbx15* genomic locus, a targeting vector, and the targeted locus generated by homologous recombination. The targeting vector contains the  $\beta$ -*geo* cassette in place of exons 3 to 7. The length of the diagnostic *Hind*III (H) restriction fragments and the locations of the 5' and 3' probes for Southern blot analyses are shown. Arrows indicate the primers for PCR analysis. The diagrams are not drawn to scale. (B) Southern blot analysis. Specific hybridization with the 5' probe produces a 10-kb band from the wild-type locus and an 8-kb band from the targeted locus. Hybridization with the 3' probe produces a 9-kb band from the wild-type locus and a 10-kb band from the targeted locus. +/+ and  $\pm$  represent genotypes of *Fbx15*<sup>+/+</sup> and *Fbx15*<sup>+/-</sup> cells, respectively. (C) PCR analysis. PCR with the three primers shown in panel A produces a 280-bp band from the wild-type locus and a 725-bp band from the targeted locus. (D) Northern blot analysis. Total RNA isolated from ES cells of each genotype was separated, blotted, and hybridized to cDNA probes of *Fbx15* and *Oct3/4*. (E) Western blot analyses. Lysates isolated from ES cells of each genotype were separated by SDS-PAGE and immunoblotted with anti-*Fbx15* serum or anti-CDK4 antibody.

cells expressed *Fbx15* even after LIF removal or retinoic acid treatment (not shown). However, those cells differentiated normally when subjected to these treatments. They also formed normal embryoid bodies and teratomas (not shown). These findings indicate that *Fbx15* alone is not capable of maintaining the undifferentiated state of ES cells.

**DISCUSSION**

Undifferentiated-cell-specific transcription factor *Oct3/4* plays essential roles in self-renewal of ES cells and mouse early development. However, only a few *Oct3/4* target genes have been identified. In this report, we presented three lines of evidence showing that *Fbx15* is a novel target of *Oct3/4*. First, the expression profile of *Fbx15* was nearly identical to that of *Oct3/4* and was restricted in ES cells, early embryos, and testis tissue. In addition, conditional inactivation of *Oct3/4* in ES

cells led to rapid disappearance of *Fbx15* transcripts. Second, analyses of the regulatory elements of *Fbx15* demonstrated that an octamer-like motif and an adjacent Sox-binding motif are crucial for its expression in ES cells. Third, a gel mobility shift assay demonstrated direct and cooperative binding of *Oct3/4* and Sox2 to the *Fbx15* enhancer. These data suggested important roles of *Fbx15* in ES cells and early development. Surprisingly, however, ES cells deficient in *Fbx15* were normal in morphology, proliferation, and pluripotency. Homozygous mutant mice developed normally and were fertile. These data, taken together, demonstrate that mouse *Fbx15* is a novel target of *Oct3/4* but is dispensable for ES cell self-renewal, early development, and fertility.

The first evidence supporting the notion that *Fbx15* is an *Oct3/4* target is the high degree of similarity in expression profiles. *Oct3/4* expression is restricted in pluripotent cells,




FIG. 10. *Fbx15* expression represented by  $\beta$ -gal activity in mutant ES cells and mice. (A) Wild-type and *Fbx15*<sup>-/-</sup> ES cells were stained with X-Gal. Cells were either maintained undifferentiated on feeder cells or induced to differentiate with retinoic acid. (B) Whole-mount X-Gal staining of testes from wild-type and *Fbx15*<sup>+/-</sup> mice. (C) Whole-mount X-Gal staining of eggs from *Fbx15*<sup>+/+</sup> and *Fbx15*<sup>+/-</sup> female mice mated with wild-type males.

including ES cells and germ cells (30). In unfertilized eggs and one-cell stage embryos, *Oct3/4* is expressed at a low level (28). Its expression level becomes higher at the four-cell stage and reaches a maximum at the eight-cell and morula stages. Our Northern blot and RT-PCR analyses showed that *Fbx15* expression was highest in ES cells, intermediate in testis tissue, and low in ovary tissue. No expression was detected in any of the other adult tissue types examined. X-Gal staining of  $\beta$ -gal knock-in mice demonstrated that *Fbx15* expression was undetectable in unfertilized eggs and one-cell stage embryos. It was activated at the two-cell stage and was highest at the eight-cell stage. Thus, *Fbx15* expression is restricted to cells and tissues where *Oct3/4* is expressed at a high level, suggesting that *Oct3/4* may control *Fbx15* gene expression.

Additional data supporting the notion that *Fbx15* is an *Oct3/4* target came from ZHBTc4 ES cells, in which both copies of the *Oct3/4* gene had been deleted by gene targeting (25). Self-renewal of these cells was maintained by transgene

expression of *Oct3/4* cDNA under control of the tetracycline-responsive element. Addition of tetracycline to culture medium resulted in rapid inactivation of the *Oct3/4* transgene. *Oct3/4* target genes, such as *Rex-1*, were rapidly repressed after transgene inactivation. Our study showed that *Fbx15* expression disappeared within 72 h after tetracycline addition. Since inactivation of *Oct3/4* led to spontaneous differentiation of ES cells, the decline in *Fbx15* may be an indirect effect. However, the rapid reduction in *Fbx15* argues that *Oct3/4* controls *Fbx15* expression.

Analyses of regulatory regions further support the notion that *Fbx15* is a novel *Oct3/4* target. Reporter gene analyses showed that the ES cell-specific enhancer (TTTATCATAAC AAT) of the *Fbx15* gene contained a sequence similar to the octamer motif (ATT[A/T]GCAT) (29) and an adjacent Sox-binding sequence (AACAAAT) (11). Deletion or point mutation of either motif abolished the enhancer activity. The enhancer was inactive in NIH 3T3 cells but became active when



Oct3/4 and Sox2 expression vectors were introduced. Furthermore, a gel mobility shift assay demonstrated direct binding of Oct3/4 and Sox2 to the enhancer. These data indicate that Oct3/4, together with Sox2, controls the *Fbx15* enhancer.

The putative Oct3/4-binding site (TTTATCAT) in *Fbx15* differs from the canonical octamer motif (ATT[A/T]GCAT) by two nucleotides (the mutations are underlined). Such variations have been documented in other cases. For example, although the octamer motif was first identified in and highly conserved among immunoglobulin genes, the human *h100* gene has a motif, ATTTTICAT, that differs from the consensus by one nucleotide (29). The Oct3/4-binding site in *UTF1* (ATCTGCAT) also differs from the consensus by one nucleotide (22). It is likely that these differences reduce affinity for Oct3/4. In consistent with this, our gel mobility shift assay suggested that Oct3/4 requires the cooperation of Sox2 for stable binding to the octamer-like sequence. This may explain why Fbx15 is undetectable in cells expressing low levels of Oct3/4, such as unfertilized eggs and one-cell stage embryos.

Fbx15 was identified as a novel F-box-containing protein. The F box was first defined in Skp2 and cyclin F as a Skp1-binding site (1). F-box-containing proteins bind Skp1 and Cul1 to form the SCF complexes that function as E3 ubiquitin ligases. In general, C-terminal portions of F-box proteins bind to substrate proteins, thus promoting their ubiquitin-dependent proteolysis. Our study showed that Fbx15 formed an SCF complex when Fbx15, Skp1, and Cul1 were overexpressed, suggesting its involvement in the ubiquitin-proteasome pathway. Fbx15 may play a role in determining the expression levels of regulatory proteins necessary for pluripotency. In B cells, the transcription coactivator OBF-1, which binds to Oct-1, Oct-2, and the octamer sequence, is regulated by ubiquitin proteasome-mediated degradation (34). A similar mechanism may operate in ES cells. However, whether endogenous Fbx15 forms the SCF complex has not been determined. Furthermore, Fbx15 lacks known domains for interaction with substrate proteins, such as leucine-rich and WD40 motifs. Recently, Fbx2 (38) and Fbx32 (3, 10), which both lack leucine-rich and WD40 motifs, were shown to function as ubiquitin ligases, suggesting the existence of novel substrate-interacting domains. Fbx15 may also bind to substrates via a novel interacting motif.

To understand the in vivo functions of Fbx15, we deleted its gene by homologous recombination in ES cells and mice. Despite its specific expression, *Fbx15*-null ES cells were normal in morphology, proliferation, and pluripotency. Mutant mice showed no gross abnormalities. Both male and female homozygous mice were fertile. These data suggest that Fbx15 does not play important roles. However, it is more likely that other genes play redundant roles, thus eliminating obvious phenotypes in *Fbx15*-null cells and mice. It is known that multiple ubiquitin ligases have the same substrates. For example, p27<sup>Kip1</sup> is still degraded in *Skp2*<sup>-/-</sup> cells (12). An EST database search showed that ES cells express various F-box proteins, including Skp2, Fbl6, and Fbl12. Some of these may compensate Fbx15 functions.

In summary, we have demonstrated three lines of evidence supporting the idea that *Fbx15* is a novel target of Oct3/4. We also generated ES cells and mice deficient in *Fbx15*. Lack of obvious phenotypes in these cells and mice suggested that

other ubiquitin ligases compensate Fbx15. Identification of Fbx15 substrates and other ubiquitin ligases that use the same substrates and simultaneous gene knockout are required to understand the roles of the ubiquitin-proteasome pathway in self-renewal of ES cells, early mouse development, and fertility.

#### ACKNOWLEDGMENTS

Y. Tokuzawa and E. Kaiho contributed equally to this work.

We are grateful to T. Ichisaka and Y. Samitsu for blastocyst microinjection. We thank C. Takigawa and J. Iida for technical assistance and R. Sasaki for plasmid construction.

This work was supported in part by grants from The Sumitomo Foundation, the Uehara Memorial Foundation, and the Japanese Ministry of Education, Culture, Sports, Science and Technology.

#### REFERENCES

- Bai, C., P. Sen, K. Hofmann, L. Ma, M. Goebel, J. W. Harper, and S. J. Elledge. 1996. SKP1 connects cell cycle regulators to the ubiquitin proteolysis machinery through a novel motif, the F-box. *Cell* **86**:263-274.
- Ben-Shushan, E., J. R. Thompson, L. J. Gudas, and Y. Bergman. 1998. Rex-1, a gene encoding a transcription factor expressed in the early embryo, is regulated via Oct-3/4 and Oct-6 binding to an octamer site and a novel protein, Rox-1, binding to an adjacent site. *Mol. Cell. Biol.* **18**:1866-1878.
- Bodine, S. C., E. Latres, S. Baumhueter, V. K. Lai, L. Nunez, B. A. Clarke, W. T. Poueymirou, F. J. Panaro, E. Na, K. Dharmarajan, Z. Q. Pan, D. M. Valenzuela, T. M. DeChiara, T. N. Stitt, G. D. Yancopoulos, and D. J. Glass. 2001. Identification of ubiquitin ligases required for skeletal muscle atrophy. *Science* **294**:1704-1708.
- Dailey, L., H. Yuan, and C. Basilico. 1994. Interaction between a novel F9-specific factor and octamer-binding proteins is required for cell-type-restricted activity of the fibroblast growth factor 4 enhancer. *Mol. Cell. Biol.* **14**:7758-7769.
- Damjanov, I. 1978. Teratoma and teratocarcinoma in experimental animals. *Natl. Cancer Inst. Monogr.* **49**:305-306.
- Damjanov, I., and D. Solter. 1974. Experimental teratoma. *Curr. Top. Pathol.* **59**:69-130.
- Dent, C. L., and D. S. Latchman. 1993. The DNA mobility shift assay, p. 1-26. In D. S. Latchman (ed.), *Transcription factors: a practical approach*. Oxford University Press, New York, N.Y.
- Evans, M. J., and M. H. Kaufman. 1981. Establishment in culture of pluripotent cells from mouse embryos. *Nature* **292**:154-156.
- Gassmann, M., G. Donoho, and P. Berg. 1995. Maintenance of an extra-chromosomal plasmid vector in mouse embryonic stem cells. *Proc. Natl. Acad. Sci. USA* **92**:1292-1296.
- Gomes, M. D., S. H. Lecker, R. T. Jagoe, A. Navon, and A. L. Goldberg. 2001. Atrogin-1, a muscle-specific F-box protein highly expressed during muscle atrophy. *Proc. Natl. Acad. Sci. USA* **98**:14440-14445.
- Haqq, C. M., C. Y. King, E. Ukiyama, S. Falsafi, T. N. Haqq, P. K. Donahoe, and M. A. Weiss. 1994. Molecular basis of mammalian sexual determination: activation of Mullerian inhibiting substance gene expression by SRY. *Science* **266**:1494-1500.
- Hara, T., T. Kamura, K. Nakayama, K. Oshikawa, and S. Hatakeyama. 2001. Degradation of p27(Kip1) at the G<sub>0</sub>-G<sub>1</sub> transition mediated by a Skp2-independent ubiquitination pathway. *J. Biol. Chem.* **276**:48937-48943.
- Li, E., T. H. Bestor, and R. Jaenisch. 1992. Targeted mutation of the DNA methyltransferase gene results in embryonic lethality. *Cell* **69**:915-926.
- Lyapina, S. A., C. C. Correll, E. T. Kipreos, and R. J. Deshaies. 1998. Human CUL1 forms an evolutionarily conserved ubiquitin ligase complex (SCF) with SKP1 and an F-box protein. *Proc. Natl. Acad. Sci. USA* **95**:7451-7456.
- Martin, G. R. 1981. Isolation of a pluripotent cell line from early mouse embryos cultured in medium conditioned by teratocarcinoma stem cells. *Proc. Natl. Acad. Sci. USA* **78**:7634-7638.
- Meiner, V. L., S. Cases, H. M. Myers, E. R. Sande, S. Bellosta, M. Schambelan, R. E. Pitas, J. McGuire, J. Herz, and R. V. Farese, Jr. 1996. Disruption of the acyl-CoA:cholesterol acyltransferase gene in mice: evidence suggesting multiple cholesterol esterification enzymes in mammals. *Proc. Natl. Acad. Sci. USA* **93**:14041-14046.
- Mitsui, K., M. Nakanishi, S. Ohtsuka, T. H. Norwood, K. Okabayashi, C. Miyamoto, K. Tanaka, A. Yoshimura, and M. Ohtsubo. 1999. A novel human gene encoding HECT domain and RCC1-like repeats interacts with cyclins and is potentially regulated by the tumor suppressor proteins. *Biochem. Biophys. Res. Commun.* **266**:115-122.
- Mortensen, R. M., D. A. Conner, S. Chao, A. A. T. Geisterfer-Lowrance, and J. G. Seidman. 1992. Production of homozygous mutant ES cells with a single targeting construct. *Mol. Cell. Biol.* **12**:2391-2395.
- Mountford, P., B. Zevnik, A. Duwel, J. Nichols, M. Li, C. Dani, M. Robertson, I. Chambers, and A. Smith. 1994. Dicistronic targeting constructs:

- reporters and modifiers of mammalian gene expression. *Proc. Natl. Acad. Sci. USA* **91**:4303–4307.
20. **Nichols, J., E. P. Evans, and A. G. Smith.** 1990. Establishment of germ-line-competent embryonic stem (ES) cells using differentiation inhibiting activity. *Development* **110**:1341–1348.
  21. **Nichols, J., B. Zevnik, K. Anastasiadis, H. Niwa, D. Klewe-Nebenius, I. Chambers, H. Scholer, and A. Smith.** 1998. Formation of pluripotent stem cells in the mammalian embryo depends on the POU transcription factor Oct4. *Cell* **95**:379–391.
  22. **Nishimoto, M., A. Fukushima, A. Okuda, and M. Muramatsu.** 1999. The gene for the embryonic stem cell coactivator UTF1 carries a regulatory element which selectively interacts with a complex composed of Oct-3/4 and Sox-2. *Mol. Cell. Biol.* **19**:5453–5465.
  23. **Niwa, H.** 2001. Molecular mechanism to maintain stem cell renewal of ES cells. *Cell Struct. Funct.* **26**:137–148.
  24. **Niwa, H., T. Burdon, I. Chambers, and A. Smith.** 1998. Self-renewal of pluripotent embryonic stem cells is mediated via activation of STAT3. *Genes Dev.* **12**:2048–2060.
  25. **Niwa, H., J. Miyazaki, and A. G. Smith.** 2000. Quantitative expression of Oct-3/4 defines differentiation, dedifferentiation or self-renewal of ES cells. *Nat. Genet.* **24**:372–376.
  26. **Niwa, H., K. Yamamura, and J. Miyazaki.** 1991. Efficient selection for high-expression transfectants with a novel eukaryotic vector. *Gene* **108**:193–199.
  27. **Okamoto, K., H. Okazawa, A. Okuda, M. Sakai, M. Muramatsu, and H. Hamada.** 1990. A novel octamer binding transcription factor is differentially expressed in mouse embryonic cells. *Cell* **60**:461–472.
  28. **Palmieri, S. L., W. Peter, H. Hess, and H. R. Scholer.** 1994. Oct-4 transcription factor is differentially expressed in the mouse embryo during establishment of the first two extraembryonic cell lineages involved in implantation. *Dev. Biol.* **166**:259–267.
  29. **Parslow, T. G., D. L. Blair, W. J. Murphy, and D. K. Granner.** 1984. Structure of the 5' ends of immunoglobulin genes: a novel conserved sequence. *Proc. Natl. Acad. Sci. USA* **81**:2650–2654.
  30. **Pesce, M., and H. R. Scholer.** 2001. Oct-4: gatekeeper in the beginnings of mammalian development. *Stem Cells* **19**:271–278.
  31. **Scholer, H. R., G. R. Dressler, R. Balling, H. Rohdewohld, and P. Gruss.** 1990. Oct-4: a germline-specific transcription factor mapping to the mouse t-complex. *EMBO J.* **9**:2185–2195.
  32. **Smith, A. G.** 2001. Embryo-derived stem cells: of mice and men. *Annu. Rev. Cell Dev. Biol.* **17**:435–462.
  33. **Thomson, J. A., J. Itskovitz-Eldor, S. S. Shapiro, M. A. Waknitz, J. J. Swiergiel, V. S. Marshall, and J. M. Jones.** 1998. Embryonic stem cell lines derived from human blastocysts. *Science* **282**:1145–1147.
  34. **Tiedt, R., B. A. Bartholdy, G. Matthias, J. W. Newell, and P. Matthias.** 2001. The RING finger protein Siah-1 regulates the level of the transcriptional coactivator OBF-1. *EMBO J.* **20**:4143–4152.
  35. **Winston, J. T., D. M. Koepp, C. Zhu, S. J. Elledge, and J. W. Harper.** 1999. A family of mammalian F-box proteins. *Curr. Biol.* **9**:1180–1182.
  36. **Yamanaka, S., X. Y. Zhang, M. Maeda, K. Miura, S. Wang, R. V. Farese, Jr., H. Iwao, and T. L. Innerarity.** 2000. Essential role of NAT1/p97/DAP5 in embryonic differentiation and the retinoic acid pathway. *EMBO J.* **19**:5533–5541.
  37. **Yamanaka, S., X. Y. Zhang, K. Miura, S. Kim, and H. Iwao.** 1998. The human gene encoding the lectin-type oxidized LDL receptor (OLR1) is a novel member of the natural killer gene complex with a unique expression profile. *Genomics* **54**:191–199.
  38. **Yoshida, Y., T. Chiba, F. Tokunaga, H. Kawasaki, K. Iwai, T. Suzuki, Y. Ito, K. Matsuoka, M. Yoshida, K. Tanaka, and T. Tai.** 2002. E3 ubiquitin ligase that recognizes sugar chains. *Nature* **418**:438–442.